Good news as cancer patients will get access to more treatments after price drops 03 Mar 2017 Pharmaceutical companies have lowered the prices of 14 key cancer medicines as part of a review by NICE of the old Cancer Drugs Fund (CDF). Find out more Show/Hide
Statement about NICE draft guidance on enzalutamide 10 Jun 2015 ICR CEO Professor Paul Workman comments on today’s rejection of enzalutamide for advanced prostate cancer before chemotherapy in draft guidance from NICE. Find out more Show/Hide